Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Pancreatic cancer cells continuously reshape DNA to evade treatment

13

Oct 2026

Pancreatic cancer cells continuously reshape DNA to evade treatment

A new analysis of nearly half a million cells from dozens of pancreatic tumors, led by researchers at UC San Diego Moores Cancer Center and New York University (NYU), reveals how pancreatic cancer cells continuously reshape their genetic makeup over time, enabling them to evade treatment.

Maternal opioid use in pregnancy linked to childhood hospitalizations

13

Oct 2026

Maternal opioid use in pregnancy linked to childhood hospitalizations

Children whose mothers received opioid prescriptions during pregnancy have a higher rate of hospital admission in childhood than unexposed children, including unexposed siblings, according to a new study published October 13th in the open access journal PLOS Medicine by Dong Keon Yon of Kyung Hee University College of Medicine, South Korea, and colleagues.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.